MarketCap
Facebook
X
Telegram
Prelude Therapeutics Incorporated EPS Ratio | PRLD
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Prelude Therapeutics Incorporated
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.29 | -1.68 | -2.02 | -2.44 | -2.43 | -4.56 | -16.5 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.29 | -16.5 | -4.42 |
Quarterly EPS Ratio Prelude Therapeutics Incorporated
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.41 | -0.13 | - | -0.26 | -0.41 | -0.42 | - | -0.43 | -0.46 | -0.42 | - | -0.45 | -0.54 | -0.58 | - | -0.63 | -0.58 | -0.63 | - | -0.66 | -0.58 | -0.47 | - | -5.25 | -5.5 | -5.12 | - | -3.93 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -0.13 | -5.5 | -1.33 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Celsion Corporation
CLSN
|
-6.83 | - | -6.63 % | $ 13.9 M |  USA |
 |
Qilian International Holding Group Limited
QLI
|
-0.18 | - | -6.08 % | $ 184 M |  China |
 |
Happiness Biotech Group Limited
HAPP
|
0.75 | - | 1.35 % | $ 17.8 M | China |
 |
Synthetic Biologics
SYN
|
-2.08 | - | 1.32 % | $ 16.2 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
0.21 | - | - | $ 2.02 B | USA |
 |
BioXcel Therapeutics
BTAI
|
-5.73 | $ 1.19 | 5.31 % | $ 14.5 M | USA |
 |
Burford Capital Limited
BUR
|
0.29 | $ 4.37 | 0.23 % | $ 958 M |  Britain |
 |
I-Mab
IMAB
|
-7.66 | - | - | $ 866 M | China |
 |
BeyondSpring
BYSI
|
-0.02 | $ 0.84 | 34.27 % | $ 34.5 M | USA |
 |
AgeX Therapeutics
AGE
|
-1.91 | - | -10.17 % | $ 12.2 K | USA |
 |
Genfit SA
GNFT
|
1.51 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-0.03 | - | -13.47 % | $ 169 M | France |
 |
Cerus Corporation
CERS
|
-0.08 | $ 2.98 | 4.93 % | $ 568 M | USA |
 |
Compugen Ltd.
CGEN
|
0.38 | $ 2.41 | 4.17 % | $ 225 M |  Israel |
 |
CureVac N.V.
CVAC
|
0.72 | - | - | $ 867 M |  Germany |
 |
Athira Pharma
ATHA
|
-24.7 | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-0.07 | - | 0.74 % | $ 768 M | Israel |
 |
Abcam plc
ABCM
|
-0.037 | - | - | $ 4.9 B | Britain |
|
Galera Therapeutics
GRTX
|
0.64 | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-0.0001 | - | -18.52 % | $ 27.3 M | Britain |
 |
Hepion Pharmaceuticals
HEPA
|
-0.88 | - | -18.79 % | $ 39.3 K | USA |
 |
ARCA biopharma
ABIO
|
-3.87 | - | 1052.0 % | $ 415 M | USA |
 |
MorphoSys AG
MOR
|
-5.53 | - | 2.43 % | $ 254 M | Germany |
|
Champions Oncology
CSBR
|
-0.08 | $ 5.1 | 2.63 % | $ 70.5 M | USA |
 |
Affimed N.V.
AFMD
|
-7.09 | - | -34.95 % | $ 21.5 M | Germany |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
-2.66 | - | -1.58 % | $ 28.1 M | China |
 |
Celyad Oncology SA
CYAD
|
-1.81 | - | - | $ 12.5 M |  Belgium |
 |
Adial Pharmaceuticals
ADIL
|
-11.9 | $ 3.98 | 1.86 % | $ 2.66 M | USA |
 |
Generation Bio Co.
GBIO
|
-1.98 | - | - | $ 344 M | USA |
 |
Akero Therapeutics
AKRO
|
-3.75 | - | - | $ 3.67 B | USA |
 |
AnaptysBio
ANAB
|
-0.46 | $ 58.47 | 4.37 % | $ 1.68 B | USA |
 |
Anika Therapeutics
ANIK
|
-0.76 | $ 21.5 | 1.56 % | $ 308 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-6.45 | - | -4.36 % | $ 27 M | USA |
 |
Gracell Biotechnologies
GRCL
|
-1.8 | - | - | $ 3.37 B | China |
 |
Aurinia Pharmaceuticals
AUPH
|
1.6 | $ 15.47 | 1.91 % | $ 2.08 B |  Canada |
 |
GlycoMimetics
GLYC
|
-0.59 | - | 9357.83 % | $ 1.01 B | USA |
 |
Aeterna Zentaris
AEZS
|
-3.27 | - | 5.93 % | $ 314 M | Canada |
 |
AVROBIO
AVRO
|
-4.05 | - | 1083.1 % | $ 745 M | USA |
 |
BeiGene, Ltd.
BGNE
|
0.2 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bicycle Therapeutics plc
BCYC
|
-3.16 | $ 3.9 | 0.24 % | $ 270 M | Britain |
 |
Beam Therapeutics
BEAM
|
-0.81 | $ 26.75 | 0.91 % | $ 2.65 B | USA |
 |
AIkido Pharma
AIKI
|
-1.57 | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
13.8 | - | - | $ 1.01 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
1.82 | $ 67.36 | 0.99 % | $ 12.9 B | USA |
 |
Aptose Biosciences
APTO
|
-10.4 | - | -45.71 % | $ 1.2 M | Canada |